Log in

NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price, Forecast & News

$5.81
+0.31 (+5.64 %)
(As of 03/29/2020 05:43 AM ET)
Today's Range
$5.45
Now: $5.81
$5.83
50-Day Range
$4.34
MA: $6.17
$7.65
52-Week Range
$3.80
Now: $5.81
$12.40
Volume2,550 shs
Average Volume7,529 shs
Market Capitalization$51.77 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.79
Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.
Read More
Aridis Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDS
CUSIPN/A
CIKN/A
Phone408-385-1742

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 million
Book Value$3.25 per share

Profitability

Net Income$-22,100,000.00

Miscellaneous

Employees23
Market Cap$51.77 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ARDS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.


Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

How has Aridis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aridis Pharmaceuticals' stock was trading at $6.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARDS stock has decreased by 10.1% and is now trading at $5.81. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aridis Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aridis Pharmaceuticals.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced its earnings results on Wednesday, November, 13th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.54. View Aridis Pharmaceuticals' earnings history.

What price target have analysts set for ARDS?

5 analysts have issued 12-month target prices for Aridis Pharmaceuticals' stock. Their forecasts range from $7.00 to $25.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $17.40 in the next twelve months. This suggests a possible upside of 199.5% from the stock's current price. View analysts' price targets for Aridis Pharmaceuticals.

Has Aridis Pharmaceuticals been receiving favorable news coverage?

Press coverage about ARDS stock has trended somewhat positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAridis Pharmaceuticals.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a increase in short interest in February. As of February 28th, there was short interest totaling 43,500 shares, an increase of 5.1% from the February 13th total of 41,400 shares. Based on an average trading volume of 18,000 shares, the short-interest ratio is currently 2.4 days. Currently, 0.8% of the shares of the company are sold short. View Aridis Pharmaceuticals' Current Options Chain.

Who are some of Aridis Pharmaceuticals' key competitors?

What other stocks do shareholders of Aridis Pharmaceuticals own?

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the following people:
  • Dr. Eric J. Patzer, Exec. Chairman (Age 70)
  • Dr. Vu L. Truong, Founder, CEO, Chief Scientific Officer & Director (Age 55)
  • Dr. Alan H. Cohen, Sr. VP of Clinical & Medical Affairs (Age 58)
  • Mr. Fred Kurland, Chief Financial Officer (Age 68)
  • Mr. Jeffrey J. Fessler J.D., Acting Gen. Counsel (Age 56)

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $5.81.

How big of a company is Aridis Pharmaceuticals?

Aridis Pharmaceuticals has a market capitalization of $51.77 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe. View additional information about Aridis Pharmaceuticals.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]


MarketBeat Community Rating for Aridis Pharmaceuticals (NASDAQ ARDS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  99 (Thanks for Voting!)
Underperform Votes:  118 (Thanks for Voting!)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Aridis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: CAC 40 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel